AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16459863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffa's fat pad resection
Number of subjects: 68
Study 16459863 — intervention group
Group type: COMPARATOR
Intervention: Hoffa's fat pad preservation
Number of subjects: 68
Study 14512102 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher methadone doses (more than 80 mg)
Number of subjects: 265
Study 14512102 — intervention group
Group type: EXPERIMENTAL
Intervention: Good quality of interpersonal relationships
Number of subjects: 265
Study 14512102 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable employment
Number of subjects: 265
Study 14512102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower craving scores
Number of subjects: 265
Study 14512102 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment associated with methadone
Number of subjects: 265
Study 14512102 — intervention group
Group type: COMPARATOR
Intervention: Weekly or twice weekly methadone administration
Number of subjects: 265
Study 10855941 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged courses of steroids
Number of subjects: 0
Study 10855941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A and cytotoxic agents
Number of subjects: 0
Study 10855941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone, azathioprine, tacrolimus, mycophenolate mofetil, combination therapy
Number of subjects: 0
Study 10855941 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study 8695243 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CEA > or = 5 micrograms/l
Number of subjects: 290
Study 8695243 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta HCG > or = 4 U/l
Number of subjects: 290
Study 8695243 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125 > or = 35 U/ml
Number of subjects: 290
Study 8695243 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125 > or = 350 U/ml
Number of subjects: 290
Study 8695243 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta HCG > or = 4 IU/l (multivariate analysis)
Number of subjects: 290
Study 8695243 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125 > or = 350 U/ml (multivariate analysis)
Number of subjects: 290
Study 1839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (120 mg)
Number of subjects: 9
Study 1839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (240 mg)
Number of subjects: 9
Study 1839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (480 mg)
Number of subjects: 9
Study 1839981 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine-HCl (dose-dependent)
Number of subjects: 9
Study 3901833 — intervention group
Group type: EXPERIMENTAL
Intervention: anterior rhinometry
Number of subjects: 49
Study 31306319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (2-octyl cyanoacrylate)
Number of subjects: 504
Study 31306319 — intervention group
Group type: COMPARATOR
Intervention: Sterile strips
Number of subjects: 504
Study 31306319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 504
Study 30048916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led structured advance care planning programme
Number of subjects: 230
Study 30048916 — intervention group
Group type: COMPARATOR
Intervention: Self-care management as attention control
Number of subjects: 230
Study 25192967 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative worst pain ratings (day 1 to day 4)
Number of subjects: 416
Study 25192967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean oral morphine intake
Number of subjects: 416
Study 25192967 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations with postoperative worst pain ratings
Number of subjects: 416
Study 25085736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual computer monitors
Number of subjects: 54
Study 25085736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dual monitors)
Number of subjects: 54
Study 22987468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer pain self-management intervention
Number of subjects: 8
Study 22987468 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored counselling by a professional
Number of subjects: 8
Study 22987468 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experiences of patients
Number of subjects: 8
Study 20200939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg) before exercise
Number of subjects: 73
Study 20200939 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo before, ibuprofen after
Number of subjects: 73
Study 20200939 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after
Number of subjects: 73
Study 17881719 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP-1347 10 mg BID
Number of subjects: 806
Study 17881719 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP-1347 25 mg BID
Number of subjects: 806
Study 17881719 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP-1347 50 mg BID
Number of subjects: 806
Study 17881719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study 15674304 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (males: 300 ml/day, 38.3 g alcohol/day; females: 200 ml/day, 25.5 g alcohol/day)
Number of subjects: 69
Study 15674304 — intervention group
Group type: COMPARATOR
Intervention: Water + red grape extract tablets (wine-equivalent dose)
Number of subjects: 69
Study 15674304 — intervention group
Group type: COMPARATOR
Intervention: Water + red grape extract tablets (half dose)
Number of subjects: 69
Study 15674304 — intervention group
Group type: COMPARATOR
Intervention: Water + placebo tablets
Number of subjects: 69
Study 12003977 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 5 days
Number of subjects: 48
Study 12003977 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-infected nasal polyps)
Number of subjects: 48
Study 9932939 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cerebral abnormalities on quantitative MRI analysis
Number of subjects: 28
Study 9932939 — intervention group
Group type: EXPERIMENTAL
Intervention: Global memory impairment
Number of subjects: 28
Study 9932939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral memory deficits
Number of subjects: 28
Study 7788197 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg
Number of subjects: 24
Study 7788197 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 1.5 mg/kg
Number of subjects: 24
Study 2316283 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell rabies vaccine (Rabipur)
Number of subjects: 0
Study 2316283 — intervention group
Group type: COMPARATOR
Intervention: Standard NIH test
Number of subjects: 0
Study 2316283 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative in vivo methods
Number of subjects: 0
Study 2316283 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ABT
Number of subjects: 0
Study 340117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol
Number of subjects: 30
Study 340117 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestronol
Number of subjects: 30
Study 340117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31174213 — intervention group
Group type: COMPARATOR
Intervention: Lean men
Number of subjects: 24
Study 31174213 — intervention group
Group type: COMPARATOR
Intervention: Obese men
Number of subjects: 24
Study 28972004 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 18144
Study 25468944 — intervention group
Group type: EXPERIMENTAL
Intervention: DM2+Met
Number of subjects: 3
Study 25468944 — intervention group
Group type: EXPERIMENTAL
Intervention: DM2
Number of subjects: 3
Study 25468944 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 3
Study 23441598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and 8 mg of ondansetron
Number of subjects: 240
Study 23441598 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and 8 mg of ondansetron
Number of subjects: 240
Study 23441598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane combined with propofol and 8 mg of ondansetron
Number of subjects: 240
Study 23441598 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 240
Study 23441598 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 240
Study 23441598 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane combined with propofol
Number of subjects: 240
Study 21054554 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia (ZrO(2)) abutments
Number of subjects: 20
Study 21054554 — intervention group
Group type: COMPARATOR
Intervention: Titanium (Ti) abutments
Number of subjects: 20
Study 21054554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ZrO(2) and Ti abutments
Number of subjects: 20
Study 19750874 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving visual field (upward or downward)
Number of subjects: 36
Study 19750874 — intervention group
Group type: COMPARATOR
Intervention: Stationary visual field
Number of subjects: 36
Study 19750874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motor responses)
Number of subjects: 36
Study 17209191 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 262
Study 17209191 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with DHA
Number of subjects: 262
Study 17209191 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 262
Study 17209191 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding and Formula Feeding
Number of subjects: 262
Study 15146102 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 59
Study 15146102 — intervention group
Group type: COMPARATOR
Intervention: Combined conjugated equine estrogen 0.625 mg and medroxyprogesterone acetate 5 mg daily (CCEP)
Number of subjects: 59
Study 11593317 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with doxorubicin/G-CSF followed by high-dose chemotherapy (HDC) with CTCb and melphalan, and dose-escalated paclitaxel at 475 mg/m2
Number of subjects: 26
Study 11593317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem cell support
Number of subjects: 26
Study 9817491 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial implantable cardioverter-defibrillator (ICD)
Number of subjects: 0
Study 9817491 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (CABG alone)
Number of subjects: 0
Study 8158507 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-based desensitizing toothpaste 1
Number of subjects: 119
Study 8158507 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-based desensitizing toothpaste 2
Number of subjects: 119
Study 8158507 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 119
Study 2966193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adrenaline infusion
Number of subjects: 12
Study 2966193 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 5470431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bicarbonate postoperatively
Number of subjects: 181
Study 5470431 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 181
Study 29793387 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telehealth monitoring
Number of subjects: 171
Study 29793387 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 171
Study 28323701 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 163
Study 26377342 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (titrated to 7.5 mg bid)
Number of subjects: 6505
Study 26377342 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6505
Study 22640686 — intervention group
Group type: EXPERIMENTAL
Intervention: Water consumption
Number of subjects: 1134
Study 22640686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit juice intake
Number of subjects: 1134
Study 21736934 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO(4))
Number of subjects: 123
Study 21736934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 18463448 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐compound scalp formulation (calcipotriol plus betamethasone dipropionate)
Number of subjects: 218
Study 18463448 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate in the same vehicle
Number of subjects: 218
Study 16796097 — intervention group
Group type: EXPERIMENTAL
Intervention: Logical presentation of pictures (e.g., enter cafeteria, pick up tray, stand in line, select food)
Number of subjects: 72
Study 16796097 — intervention group
Group type: COMPARATOR
Intervention: Random presentation of pictures
Number of subjects: 72
Study 12900588 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg (up-titrated to 80 mg if needed)
Number of subjects: 0
Study 12900588 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg (up-titrated to 100 mg if needed)
Number of subjects: 0
Study 12900588 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40/80 mg
Number of subjects: 0
Study 12900588 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50/100 mg
Number of subjects: 0
Study 11035321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage (McDonald cerclage)
Number of subjects: 61
Study 11035321 — intervention group
Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 61
Study 9371668 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g/day
Number of subjects: 0
Study 9371668 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g/day
Number of subjects: 0
Study 9371668 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA 1-2 mg/kg/day
Number of subjects: 0
Study 9371668 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 0
Study 9371668 — intervention group
Group type: COMPARATOR
Intervention: MMF 2 g
Number of subjects: 0
Study 9371668 — intervention group
Group type: COMPARATOR
Intervention: MMF 3 g
Number of subjects: 0
Study 1405686 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose steroids (10 mg methylprednisolone IV intraoperatively, 10 mg IM daily for 10 days, 250 mg hydrocortisone succinate endobronchially before extubation, 5 mg methylprednisolone daily in aerosol solution)
Number of subjects: 20
Study 1405686 — intervention group
Group type: COMPARATOR
Intervention: No steroids (control group)
Number of subjects: 20
Study 3893610 — intervention group
Group type: EXPERIMENTAL
Intervention: Conray 420
Number of subjects: 482
Study 3893610 — intervention group
Group type: COMPARATOR
Intervention: Conray 280
Number of subjects: 482
Study 3893610 — intervention group
Group type: EXPERIMENTAL
Intervention: Uromiro Sodium 300
Number of subjects: 482
Study 3893610 — intervention group
Group type: EXPERIMENTAL
Intervention: Niopam 370
Number of subjects: 482
Study 3893610 — intervention group
Group type: EXPERIMENTAL
Intervention: Urografin 370
Number of subjects: 482
Study 3893610 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor reactions
Number of subjects: 482
Study 3893610 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic agents
Number of subjects: 482
Study 3893610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salt of an ionic agent
Number of subjects: 482
Study 31505986 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally acting generic drug (T)
Number of subjects: 0
Study 31505986 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovator drug (R)
Number of subjects: 0
Study 31505986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study 29570772 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg daily aspirin for 3 years
Number of subjects: 1121
Study 29570772 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg daily aspirin for 3 years
Number of subjects: 1121
Study 29570772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1121
Study 29570772 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 1 mg daily for 6 years
Number of subjects: 1121
Study 26567804 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 0
Study 24453026 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted pre- and post-contrast (T1+Gd) images
Number of subjects: 67
Study 24453026 — intervention group
Group type: COMPARATOR
Intervention: Short tau inversion recovery (STIR) images
Number of subjects: 67
Study 22534058 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O (inside-out approach)
Number of subjects: 341
Study 22534058 — intervention group
Group type: EXPERIMENTAL
Intervention: TOT-Aris (outside-in approach)
Number of subjects: 341
Study 22534058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 341
Study 20852299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac Echocardiography (ICE)
Number of subjects: 95
Study 20852299 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal Echocardiography (TEE)
Number of subjects: 95
Study 20852299 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE
Number of subjects: 95
Study 20852299 — intervention group
Group type: COMPARATOR
Intervention: TEE
Number of subjects: 95
Study 17987879 — intervention group
Group type: EXPERIMENTAL
Intervention: meridol toothbrush
Number of subjects: 171
Study 17987879 — intervention group
Group type: COMPARATOR
Intervention: ADA toothbrush
Number of subjects: 171
Study 15860185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 14920
Study 15860185 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 14920
Study 15860185 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 14920
Study 15860185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14920
Study 12421155 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A for tension-type headache
Number of subjects: 0
Study 12421155 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A for migraine
Number of subjects: 0
Study 12421155 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A for cervicogenic headache
Number of subjects: 0
Study 12421155 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A for cluster headache
Number of subjects: 0
Study 12421155 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A for chronic paroxysmal hemicrania
Number of subjects: 0
Study 10350245 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day of tirilazad mesylate
Number of subjects: 819
Study 10350245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (citrate vehicle)
Number of subjects: 819
Study 8596222 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental schedule (9 visits)
Number of subjects: 2764
Study 8596222 — intervention group
Group type: COMPARATOR
Intervention: Control schedule (14 visits)
Number of subjects: 2764
Study 2006660 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with a combination of triamterene and hydrochlorothiazide
Number of subjects: 840
Study 2006660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study 7341219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg s.c.)
Number of subjects: 18
Study 7341219 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.5 mg s.c.)
Number of subjects: 18
Study 31050818 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 828
Study 31050818 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia (IA)
Number of subjects: 828
Study 30462194 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic dilatation
Number of subjects: 41
Study 30462194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham dilatation)
Number of subjects: 41
Study 27553192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin lispro (48 or 80 IU followed by 160 IU)
Number of subjects: 14
Study 27553192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin lispro (24 IU/kg or 192 IU/kg) in beagle dogs
Number of subjects: 14
Study 27553192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin lispro
Number of subjects: 14
Study 26549483 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day practical course in surgical skills for maxillofacial surgery
Number of subjects: 54
Study 24387642 — intervention group
Group type: COMPARATOR
Intervention: Facial Mask (FM)
Number of subjects: 12
Study 24387642 — intervention group
Group type: COMPARATOR
Intervention: Helmet Standard (HS)
Number of subjects: 12
Study 24387642 — intervention group
Group type: COMPARATOR
Intervention: Helmet Next (HN)
Number of subjects: 12
Study 24387642 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet Next (HN) at increased settings
Number of subjects: 12
Study 22385260 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg systemic doxycycline (DOXY) for 7 days after surgery
Number of subjects: 61
Study 22385260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC) for 7 days after surgery
Number of subjects: 61
Study 19670918 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (15-45 mg once daily)
Number of subjects: 2097
Study 19670918 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide (5-15 mg once daily)
Number of subjects: 2097
Study 19670918 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 2097
Study 19670918 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 2097
Study 17454066 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide dispersible tablet (10 mg)
Number of subjects: 18
Study 17454066 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (conventional tablet)
Number of subjects: 18
Study 15281473 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (64 microg/d)
Number of subjects: 78
Study 15281473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78